Consequently, the paradoxical transition of ERRFI1 from a tumor suppressor that can mitigate the oncogenic effect of GC to a tumorigenic factor in advanced TNBC, in addition to the complex transcriptional network coordinated by GR, may partially explain the ineffective or adverse outcomes of GC therapy in TNBC. This evidence concerns the gene NR3C1 and neoplasm.